Compare iShares MSCI South Africa ETF (EZA) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI South Africa ETF trades at $63.8 (market cap $455.34M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 88.8× iShares MSCI South Africa ETF's market cap, and iShares MSCI South Africa ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 70 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EZA | IDXX | |
|---|---|---|
Market Cap | $455.34M | $40.43B |
Volume | 148,692 | 692,164 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $766.68 |
52-Week Low | $60.43 | $504.70 |
Typical Hold Time | 70 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $63.8, up 2.42% today, but technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces resistance near $64 and support at $61. Recent news highlights a brief price surge above the 50-day moving average in September but ongoing macroeconomic pressures from South Africa's exposure to commodities and financials.
The outlook remains cautious due to global reflation and high capital costs weighing on EZA's holdings. Risks include commodity price volatility and interest rate sensitivity, while potential upside hinges on stabilization in South African markets. Investors should weigh the ETF's concentrated exposures against broader emerging market uncertainties.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
